← Back to Search

[18F]-FEOBV PET Scan for Cognitive Function in Down Syndrome

Phase 2
Recruiting
Led By Alexander C Conley, Ph.D.
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Mental Age of 4 years or greater (based upon the Kaufman Brief Intelligence Test, 2nd Edition)
English must be first/native language
Must not have
For participants undergoing CSF collection: a current blood clotting or bleeding disorder, or significantly abnormal PT or PTT at screening or if on anti-coagulation (e.g warfarin)
Participants unable to complete MRI and PET procedures
Timeline
Screening 3 weeks
Treatment Varies
Follow Up analysis will be completed at study completion in approximately 3 years.
Awards & highlights
No Placebo-Only Group

Summary

This trialwill study how changes in cholinergic neurons affect adults with Down Syndrome, to inform treatments that could improve cognitive functioning.

Who is the study for?
Adults aged 18-55 with Down syndrome, including mosaic DS or partial trisomy 21, who are in good health without dementia and have a mental age of at least 4 years. Participants must not be pregnant, able to complete MRI and PET scans, and should not have significant medical conditions that could affect testing or contraindications for MRI.
What is being tested?
The trial is studying the integrity of cholinergic neurons in adults with Down syndrome using [18F]-FEOBV Radiotracer. It aims to understand how these neurons' condition correlates with cognitive deficits related to aging and Alzheimer's Disease pathology.
What are the potential side effects?
While specific side effects are not detailed for this study involving [18F]-FEOBV Radiotracer, typical risks may include discomfort at injection site, allergic reactions to the tracer substance used during PET scanning procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My mental age is 4 years or older according to the Kaufman test.
Select...
English is my first language.
Select...
I have been diagnosed with Down syndrome.
Select...
I can see and hear well enough for brain function tests.
Select...
I am generally healthy and do not have dementia.
Select...
I am between 18 and 55 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have a blood clotting disorder or abnormal bleeding, and I am not on strong blood thinners like warfarin.
Select...
I cannot undergo MRI and PET scans.
Select...
I do not have any major health issues that could affect brain function tests.
Select...
I have been diagnosed with dementia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~analysis will be completed at study completion in approximately 3 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and analysis will be completed at study completion in approximately 3 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
[18F]-FEOBV radiotracer standardized uptake value ratio correlation with the Basal Forebrain Cholinergic System Volume.
Secondary study objectives
EEG resting state power correlation with [18F]-FEOBV radiotracer standardized uptake value ratio

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Down SyndromeExperimental Treatment1 Intervention
Adults between 18-55 with Down Syndrome.

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
901 Previous Clinical Trials
938,662 Total Patients Enrolled
Vanderbilt Kennedy CenterOTHER
2 Previous Clinical Trials
140 Total Patients Enrolled
Alexander C Conley, Ph.D.Principal InvestigatorVanderbilt University Medical Center

Media Library

Down Syndrome Clinical Trial Eligibility Overview. Trial Name: NCT05231798 — Phase 2
Alzheimer's Disease Research Study Groups: Down Syndrome
Alzheimer's Disease Clinical Trial 2023: Down Syndrome Highlights & Side Effects. Trial Name: NCT05231798 — Phase 2
Down Syndrome 2023 Treatment Timeline for Medical Study. Trial Name: NCT05231798 — Phase 2
~5 spots leftby Nov 2025